Ketamine has shown promise in treating major depression, but its safety for patients with both social isolation and alcohol ...

St John of God Hospital in Dublin has said it is the first hospital in Ireland to introduce a special treatment for patients ...

A new non-invasive treatment for depression, which has been shown to deliver remission for one third of its patients, is to ...

After SPN-820's failure, Supernus is relying on its non-stimulant ADHD drug Qelbree and the recently approved Parkinson’s ...

The phase IIb study results of Supernus Pharmaceuticals Inc.’s SPN-820 in treatment-resistant depression had pulled the company’s stock (NASDAQ:SUPN) down 15.6% on Feb. 19. The randomized, ...

Investigational drug SPN-820, which activates the mTORC1 pathway, failed to significantly reduce depressive symptoms compared ...

Major depressive disorder (MDD) is a leading cause of disability worldwide, with a significant proportion of patients (10-20%) progressing to treatment-resistant depression (TRD).

Supernus Pharmaceutical’s stock declined following the release of disappointing Phase IIb trial results for SPN-820, an ...

Supernus' SPN-820 Phase 2b study in treatment-resistant depression failed to meet its primary endpoint, prompting further ...

Supernus Pharmaceuticals (NASDAQ:SUPN) stock drops as depression candidate SPN-820 misses main goals in Phase 2b trial. Read more here.

Supernus Pharmaceuticals (NASDAQ:SUPN) lost ~20% in the premarket on Wednesday after the neuro-focused biopharma said its ...

Supernus Pharmaceuticals may have had a potential path forward for its depression drug candidate cut off after the asset ...